Drosophila Models of Neurodegenerative Disease

Tzu-Kang Sang and George R. Jackson

Neurogenetics Program, Department of Neurology, Brain Research Institute, Center for Neurobehavioral Genetics,
Neuropsychiatric Institute, David Geffen School of Medicine at UCLA, Los Angeles, California 90095

Summary: Over the last two decades, a number of mutations have been identified that give rise to neurodegenerative disorders, including familial forms of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Although in most cases sporadic cases vastly outnumber familial forms of such diseases, study of such inherited forms has the potential to provide powerful clues regarding the pathophysiological basis of neurodegeneration. One powerful approach to analyzing disease mechanisms is the development of transgenic animal models, most notably in the mouse. However, development and analysis of such models can be costly and time consuming.

Development of improved transgenic technologies have contributed to the development of *Drosophila* models of a number of neurodegenerative disorders that have shown striking similarities to the human diseases. Moreover, genetic screens using such models have begun to unravel aspects of the pathophysiological basis of neurodegenerative disorders. Here, we provide a general overview of fly models pertinent to trinucleotide repeat expansion disorders, Alzheimer's, and Parkinson's diseases, and highlight key genetic modifiers that have been identified to date using such models. **Key Words:** *Drosophila*, transgenic animal, polyglutamine, tau, α -synuclein.

INTRODUCTION

What can *Drosophila* models contribute to our understanding of neurodegenerative disorders? Even 10 years ago, most academic neurologists and neurobiologists would have answered, "Nothing," and this would have been not far from the truth. However, recent advances in our understanding of the molecular basis of neurodegenerative disease and *Drosophila* genetics have enabled engineering of the simple fruit fly to create models that have shed light on the pathophysiological basis of neurological disorders afflicting humans. Considerable advances have also been made in study of learning, memory, and circadian rhythms that are of great interest; however, these will not be reviewed here. Rather, this review will focus on a number of studies that have employed targeted misexpression of human disease-associated proteins to model trinucleotide repeat expansion disorders, Alzheimer's disease (AD), and Parkinson's disease (PD). This is not intended to be a comprehensive view because this field has expanded considerably; rather, the reader without a background in fly genetics should be able to appreciate the contributions that fly

models in general have made to our understanding of neurodegenerative disorders. We will also briefly consider reverse genetic approaches that have targeted fly homologs of human neurodegenerative disease-associated genes.

GENETIC APPROACHES TO STUDY OF NEURODEGENERATION

Three quarters of the approximately 100 genes implicated in specific human diseases have at least one homolog in *Drosophila*. An online database of on human disease genes with fly homologs is available (<http://superfly.ucsd.edu/homophila/>).

Homologs of human neurodegenerative disease genes can be identified in the *Drosophila* genome. The function of these genes can then be studied by generating mutations in the *Drosophila* homolog and then studying the resulting phenotypes (if any). Just such an approach has recently been applied to study the fly homologs of ataxin-2, the gene mutated in spinocerebellar ataxia 2,¹ and in parkin,^{2,3} a gene associated with autosomal recessive juvenile parkinsonism (discussed in more detail below). Studies of the fly homolog of atrophin, a gene in which a CAG expansion gives rise to dentatorubral pallidolysian atrophy (DRPLA), have revealed its role as a transcription factor.⁴ An alternative

Address correspondence and reprint requests to George R. Jackson, 4357C Gonda Center for Neuroscience and Genetics, 695 Charles E. Young Drive South, Los Angeles, CA 90095. E-mail: grjackson@mednet.ucla.edu.

approach uses RNA interference-mediated knock down of gene expression. Such an approach has identified a role for the fly homolog of huntingtin in regulation of axonal transport and cell death.⁵

WHY STUDY NEURODEGENERATION IN FLIES?

A pathogenic process of interest in humans can be studied in flies if it can be recapitulated in a manner showing characteristics similar to those observed in man. If so, genetic approaches can be applied to order to study this pathogenic process. Mutations can be generated that affect a relevant pathogenic process without making *a priori* assumptions about pathways involved. This potential of genetic approaches to elucidate pathogenic processes makes flies such a powerful model system in neurobiology.

HOW SIMILAR ARE FLIES AND HUMANS?

Implicit in studies of invertebrate models of neurodegenerative disorders is the assumption that essential features underlying biology of humans and flies are conserved. How similar are humans and *Drosophila*? Generally speaking, fundamental aspects of cell biology are quite similar in man and flies, including regulation of gene expression, membrane trafficking, the cytoskeleton, neuronal connectivity, synaptogenesis, cell signaling, and cell death. Many genes and pathways that originally were studied in flies have subsequently been identified in mammals. As an example, the *wingless* pathway in *Drosophila* was named for a mutation originally identified in a spontaneously occurring mutant that was noted to have no wings.⁶ The mammalian homolog of the *Drosophila wingless* gene, Wnt, is now known to stand at the apex of the Wnt pathway also conserved in mammals that is crucial for cell polarity, differentiation, and migration, cytoskeletal regulation, synapse formation, and axon guidance during neuronal development.⁷

HOW DIFFERENT ARE FLIES AND HUMANS?

Of course, there are also important differences between flies and humans that must be borne in mind when interpreting genetic models. As an example, flies have much simpler circulatory systems and cognitive processes. In some circumstances, the relative simplicity of fly as compared with human genomic organization provides benefits with regard to genetic analysis. Often, redundancy exists in humans, where duplicated versions of genes are identified that are present in only one copy in flies; this lack of redundancy can simplify analysis of biological process in the fly. Perhaps the most important

aspect of invertebrate approaches is the availability of a number of genetic manipulations that are impossible or impractical to carry out in mammals. Large numbers of flies and worms can be mutagenized and screened in a short period of time, thus permitting the identification of even rare mutations. Given the considerable success that fly genetic approaches have had in delineating processes such as cell cycle control, signal transduction, and pattern formation, it is reasonable to anticipate that similar approaches to the study of neurodegeneration will continue to yield powerful insights into disease mechanisms.

USING THE FLY EYE AS A MODEL

In 1910, the first *Drosophila melanogaster* mutant was noticed by an undergraduate dishwasher in the Morgan lab at Columbia who discovered a white-eyed fly among wild-type red-eyed flies. The eye continues to be the focus of research not only because, as Morgan demonstrated, adult eye phenotypes are easy to detect, but also because, unlike most organs in the fly, the eye is tolerant of genetic disruption of basic biological processes. Moreover, under laboratory conditions, the eye is dispensable for survival of the fly. Versatile technologies that can be used to generate, identify, and characterize mutations in the retina have elevated the eye to a system with unrivaled potential for deciphering gene function. A large body of literature indicates the fly eye can be used to study processes including cell cycle control, cell proliferation and differentiation, neuronal connectivity, apoptosis, programmed cell death, and tissue patterning.

TRINUCLEOTIDE REPEAT EXPANSIONS

Glutamine repeat disorders

Huntington's disease (HD) is the prototypic disease caused by expansion of unstable CAG repeat, resulting in expression of an expanded polyglutamine tract near the amino terminus of a gene known as huntingtin.⁸ Other diseases in this class include spinocerebellar ataxias (SCA) 1, 2, 3 (also known as Machado-Joseph disease, MJD), 6, and 7, DRPLA, and spinobulbar muscular atrophy (also known as Kennedy's disease).⁹ Table 1 summarizes a number of glutamine repeat disorders that have been modeled in *Drosophila*. The first neurodegenerative disease model reported in the fly used a fragment of mutant ataxin-3/MJD¹⁰; this report was followed shortly by a model for HD using fragments of huntingtin.¹¹ Other investigators examined the effects of quasi-pure polyglutamine tracts, or polyglutamine tracts expressed within the context of fly genes, such as *prospero* and *disheveled*. Models using expression of full-length ataxin-1 and -3 also have been reported.

Figure 1 compares external eye phenotypes and retinal histology in several polyglutamine fly models. Wild-type

TABLE 1. Summary of Fly Models of Glutamine Repeat Disorders

Protein Context	Repeat Length	Reference
Pure polyglutamine	Q48	33
	Q108	34
	Q63	35
	Q79	36
	Q92	36
	Q127	18
Ataxin-1	Full-length Q82	37
	Full-length Q82	38
	Full-length Q82	39
Ataxin-3	Truncated Q78	10
	Full length Q78	40
Huntingtin	Truncated Q75 (1–171)	11
	Truncated Q120 (1–171)	11
	Truncated Q93 (exon 1)	28
	Truncated Q97 (exon 1)	41
	Truncated Q103deltaP	41
	Truncated Q128 (1–548)	42
Androgen receptor	Full-length Q52	43
	Truncated Q52	43
	Truncated Q112	44

(control) eyes shown normal external morphology of the compound eye, whereas the internal structure shows regular arrays of ommatidia, the individual units of the *Drosophila* retina. Each ommatidium at the level shown contains seven photoreceptor neurons, each of which elaborates a membranous structure, the rhabdomere, which functions in phototransduction. In a normal eye, these rhabdomeres form a characteristic seven subunit chevron-like shape (FIG. 1F). In flies expressing a mutant huntingtin fragment including 120 glutamine residues (“htt-Q120”), appearance of the eye is normal (FIG. 1B), whereas by 10 days after eclosion (“hatching”), disruption of rhabdomere structure and loss of photoreceptor neurons is apparent (FIG. 1G). Expression of the

FIG. 1. Phenotypes of fly eye models of polyglutamine disease. A–F: SEM images. F and G: toluidine blue-stained tangential retinal sections. H–J: confocal images of whole mount retina. H–I: red, TRITC-phalloidin; blue, lamin D₀. Green: H, htt17, I, anti-HA, J, anti-ataxin-1. Scale bars: A–E, 100 μ m. F–J, 10 μ m. **FIG. 2.** Immunostaining of polyglutamine aggregates in adult Q108 retina. Scale bar, 10 μ m.

quasi-pure polyglutamine tract Q108 produces disruption of the external crystalline lattice of the eye, a so-called “rough” eye (FIG. 1C). The internal structure of the retina is completely disrupted, with abnormal rhabdomere remnants and perinuclear and nuclear polyglutamine aggregates. In some cases, multilamellated spherical structures are formed, which are likely to represent autophagosomes (FIGS. 1H and 2). A mutant MJD fragment including 78 glutamine repeats also produced a rough external eye, which tends to collapse under vacuum during scanning electron microscopy (SEM). Internal structure of the retina is disrupted, with formation of intranuclear aggregates. Full-length ataxin-1 with 82 glutamine residues also produced an abnormal external eye (FIG. 1E), although the internal structure is not very abnormal (data not shown). Figure 1J shows the phenotype caused by two copies of the mutant ataxin-1 transgene, which does produce severe disruption of the retina. In our hands, in the fly retina, unlike mouse, the majority of ataxin-1 is cytoplasmic, although some nuclear aggregates are observed.

Polyglutamine-containing aggregates in mouse and cell models contain a number of additional proteins, including chaperonins and proteasome components.^{12–16} Autophagosome-like bodies in the Q108 model also contain some of these components, as indicated in Figure 2. These structures contain one or more layers of filamentous actin, as indicated by phalloidin staining, as well as polyglutamine and ubiquitin (FIG. 1, A and B). Staining for endogenous fly heat shock protein (hsp) 70 also shows that this chaperonin is present in these aggregates (FIG. 2C).

Both candidate-based and unbiased genetic screens in the fly have begun to identify polyglutamine modifiers. The first of these modifiers to be reported was hsp70; misexpression of a human hsp70, HSPAL, dramatically suppresses the eye phenotype of SCA3 flies.¹⁷ An unbiased transposon-based screen subsequently identified *Drosophila* HDJ1, an hsp40; misexpression of HDJ1 dramatically suppressed a quasi-pure polyglutamine phenotype.¹⁸

Figure 3 compares the effects of misexpression of HSPA1L and HDJ1 on the Q108 eye phenotype. One aspect of the Q108 phenotype that is not apparent using

FIG. 3. Suppression of Q108 eye phenotypes by chaperonins.

SEM is severe depigmentation; as compared with control flies (FIG. 1C), the Q108 eye shows, in addition to a rough external appearance, depigmentation (FIG. 3B). Although it is treacherous to evaluate suppression of eye phenotypes based solely on rescue of depigmentation phenotypes (because additional transgenes provide additional pigmentation irrespective of the insert DNA), moderate rescue of pigmentation, as well as improvement in the rough eye phenotype, is observed when HSPA1L is coexpressed with Q108 (FIG. 3C). By contrast, the depigmentation phenotype of Q108 is dramatically suppressed by coexpression of HDJ1 (FIG. 3D). Suppression of the rough external eye phenotype of ataxin-1 by HSPA1L and HDJ1 also has been reported.¹⁹

The role of apoptotic pathways in cell death in glu-

tamine repeat disorders is controversial; however, in the case of HD, at least, sufficient evidence exists in animal models implicating caspases-1 and -3 in pathophysiology to support clinical trials of minocycline, an antibiotic with caspase inhibitor activity.^{20–23} In flies, expression of the baculoviral antiapoptotic protein P35 or its fly counterpart, DIAP1/Thread, dramatically suppresses reduced eye phenotypes caused by overexpression of cell death genes.^{24,25} Results of experiments testing suppression of polyglutamine phenotypes in the fly eye have been inconsistent. P35 suppresses ataxin-1¹⁹ and -3^{10,19} phenotypes, but enhances Q127¹⁹ and has no effect on Q108²⁶ or htt-Q120.¹¹ Similar patterns are observed for DIAP1: suppression of ataxins-1 and -3,¹⁹ no effect on Q127¹⁹ or Q108²⁶ or htt-Q120 (Salecker, I., and G. R. Jackson, unpublished data). These data suggest that the protein context in which polyglutamine is expressed affects responsiveness to modifiers.

A candidate-based approach examining cell death regulators for modulation of polyglutamine phenotypes revealed striking suppression of Q108 and htt exon1 phenotypes by inactivation of *Drosophila* Apaf-1, Dark.²⁶ Figure 4 compares the effects of homozygous mutation of fly Apaf-1 on external and internal retinal phenotypes. In a genetic background in which both copies of Dark were mutant, dramatic suppression of Q108 and htt exon1 phenotypes was observed, as well as suppression of caspase activation, cell death, and most surprisingly, aggregate formation. The observation that virtually complete suppression of polyglutamine toxicity *in vivo* is accompanied by reduced aggregation could be considered evidence that aggregates are toxic, although this is highly controversial²⁷ and not likely to be proven or disproven using fly models.

Drosophila models have also proved useful in validation of small molecule compounds predicted to inhibit aggregation based on cell-based studies. Studies of histone deacetylase inhibitors as suppressors of mutant htt exon 1 toxicity in the fly have led to validation in mouse models and clinical trials of phenylbutyrate in HD.^{28–30} Recently, rapamycin has been demonstrated to suppress htt-Q120 toxicity, lending credence for a role of autophagy in polyglutamine disease.³¹ Other studies have identified an inhibitor of the Rho-associated kinase p160ROCK as a suppressor of mutant htt exon1 toxicity in the fly.³²

Noncoding repeat expansion disorders

Trinucleotide repeat expansion disorders include, apart from the glutamine repeat disorders already discussed, intronic expansions (e.g., Friedreich's ataxia), as well as noncoding disorders such as SCA8 and myotonic dystrophy.^{45–47} Recently, investigators have begun to use *Drosophila* to shed light on such noncoding disorders. SCA8 is associated with a CUG repeat expansion within

FIG. 4. Suppression of Q108 toxicity by homozygous mutation of fly Apaf-1. A and B: SEM images. C and D: Confocal staining of pupal eye (30%). Red: phalloidin-TRITC. Blue: lamin D₀. Green: htt17.

a noncoding transcript.⁴⁶ Rebay and colleagues⁴⁸ developed a model of SCA8 in flies that resulted in retinal degeneration, and they isolated RNA binding proteins as modifiers of this phenotype. These findings argue that RNA rather than expanded protein is an effective agent of toxicity. Myotonic dystrophy type I is associated with CTG repeat expansion in the 3' untranslated region of the dystrophin myotonia protein kinase gene. Monckton and colleagues⁴⁹ developed a model by fusing noncoding CUG repeats to reporter genes and demonstrated that these form ribonuclear foci; however, these repeats were not toxic. Fragile X syndrome is also associated with noncoding repeat expansion.⁵⁰ In this case, CGG expansion in the 5' untranslated region of the FMR1 gene leads to transcriptional silencing and loss of expression of Fragile X Mental Retardation Protein. Moses and colleagues⁵¹ expressed pathological CGG repeats fused to a reporter gene and demonstrated retinal degeneration in the absence of expressed proteins. These findings support the utility of *Drosophila* in modeling noncoding repeat expansions as well as glutamine repeat disorders, and additional such models are likely to appear in future.

ALZHEIMER'S DISEASE

Amyloid

One of the key neuropathological features of Alzheimer's disease is the extracellular amyloid plaque. The main component of these plaques is the A β peptide, which is derived from membrane bound amyloid precursor protein (APP).⁵² APP can be processed by two pathways: the amyloidogenic pathway, which results in production of A β , or the nonamyloidogenic pathway, which generates a secreted form of APP. Dominant mutations in APP or presenilins 1 and 2 cause early onset familial Alzheimer's disease.^{53,54} Homologs of APP and presenilin are found in *Drosophila*. The fly APP homolog, *Appl*, does not contain the segment of APP cleaved to generate pathogenic peptides. Still, genetic approaches have been informative regarding the role of *Appl* in flies. Flies homozygous for large deletions in *Appl* show defective locomotor behavior, and a human β -APP transgene rescues this behavior.⁵⁵ A role for *Appl* in synaptogenesis in flies has been suggested.⁵⁶

Recently, several groups have reported fly models using misexpression of A β . Iijima and colleagues⁵⁷ used a signal peptide derived from pre-proenkephalin fused to A β to generate secreted transgene products. The expression of A β 42, the more toxic peptide, led to the formation of diffuse extracellular amyloid, impaired olfactory associative learning, and neurodegeneration. A related group of investigators studied the effects of similar constructs in the eye and demonstrated retinal degeneration.⁵⁸ They also performed a genetic screen and isolated neprilysin 2 as a modifier that suppressed the A β 42

phenotype when overexpressed. Neprilysin has previously been implicated in A β degradation,⁵⁹ supporting the utility of flies as reagents to identify therapeutic targets. Greeve and colleagues⁶⁰ also have reported retinal neurodegeneration and amyloid plaque-like formation in flies that coexpress APP and either β -secretase (see below) or a dominant-negative form of presenilin. Goldstein and colleagues^{61,62} have studied impairment of axonal transport by APP in *Drosophila*, mice, and AD brain.

β - and γ -secretase are responsible for generation of pathogenic A β peptides. Although β -secretase has been characterized, the proteins responsible for γ -secretase activity have proved more elusive.⁵² One component of the γ -secretase complex is presenilin. The *Drosophila* presenilin homolog, *Psn*, has been characterized. Mutations give rise to phenotypes reminiscent of *Notch* mutants.^{63,64} *Psn* is required for normal proteolytic processing of *Notch*. Other components of the γ -secretase complex have been identified using invertebrate approaches, including *Caenorhabditis elegans* and *Drosophila* genomics.⁶⁵ These include nicastrin, Aph-1, and Pen-2. Homologs of each are present in *Drosophila*, and each component appears competent to serve as part of a γ -secretase complex.⁶⁶ A sensitized genetic system using a GAL4-responsive rough eye phenotype to identify other components of the γ -secretase complex has been reported.⁶⁷

Tauopathies

The second key feature of AD pathology is the neurofibrillary tangle (NFT). However, neurofibrillary pathology also is seen in a number of other disorders collectively referred to as tauopathies, including frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy, and corticobasal degeneration.⁶⁸ Tau is a microtubule-associated protein, and its interaction with microtubules is negatively regulated by phosphorylation of sites in or near its microtubule binding repeats. Aberrant regulation of tau phosphorylation, and thus microtubule binding, is thought to occur in tauopathies. Tau hyperphosphorylation is thought to be an early event in the cascade leading from soluble to insoluble tau protein.

Drosophila models of tauopathy have been reported. The fly tau homolog has been cloned and characterized.⁶⁹ Williams and co-workers⁷⁰ found that human tau overexpression in sensory neurons produced a number of abnormal morphologic effects, including axonal loss and swelling. Sensory neurons expressing tau underwent axonal degeneration. More recently, these authors showed that misexpression of a constitutively active form of the tau kinase glycogen synthase kinase (GSK)-3 β enhanced impaired axonal transport defects and motor behavior caused by tau.⁷¹ Wittman and co-workers⁷² overex-

FIG. 5. Enhancement of the tau eye phenotype by coexpression of Shaggy.

pressed wild type, as well as the FTDP-17-associated mutants R406W and V337M mutant tau in *Drosophila* CNS. Neuronal loss and vacuolization were observed with both wild type and R406W tau, although pathology was generally more severe with mutant tau. Immunoreactivity for various phosphotau epitopes increased over time. However, no neurofibrillary pathology was observed. Thus, although robust, adult onset, progressive neurodegeneration was observed, the fly model did not show any neurofibrillary changes. When expressed in the retina, a rough eye phenotype was observed with R406W but not wild-type tau; this observation is important because the rough eye phenotype greatly simplifies modifier screens. More recently, tau modifiers recovered from a genetic screen have been reported by Feany and co-workers.⁷³ These consist largely of kinases and phosphatases, confirming the importance of phosphorylation of tau in its pathogenicity. However, whether any of these modifiers led to changes in tau phosphorylation or solubility was not reported. Tau misexpression also has been reported to compromise olfactory learning and memory.⁷⁴

Our laboratory has also established models of tauopathy using wild-type⁷⁵ and P301L tau, an FTDP-17-associated mutation (our unpublished data). We have not obtained convincing evidence that mutant tau is more toxic than wild type. Expression of wild-type tau in the eye results in early onset cell death and adult rough eye phenotypes but not the development of any obvious neurofibrillary pathology. However, coexpression of Shaggy (Sgg), the fly homolog of the tau kinase GSK-3, enhances tau toxicity dramatically. Figure 5 compares the effects of expression of Sgg, tau, and the synergistic effects obtained when the two are coexpressed. Pan-neural expression of Sgg alone has no effect on external eye phenotype (FIG. 5A). Wild-type tau alone produces a mild rough eye phenotype when expressed throughout the retina (FIG. 5B); however, dramatic synergy is observed when tau and Sgg are coexpressed, resulting in a severely rough eye (FIG. 5C). Expression of the NFT-related phosphoepitope AT100 is observed in dual tau + Sgg transgenics, and insoluble filamentous materials, including straight and paired helical filaments, are observed. These observations support the contention that phosphorylation of tau leads to formation of NFT *in vivo*.

Others have confirmed the enhancement of tau pathogenicity by Sgg coexpression and have suggested that phosphorylation by the kinase PAR-1 is required for subsequent phosphorylation by other kinases such as GSK-3.⁷⁶

PARKINSON'S DISEASE

α -Synuclein

Parkinson's disease is an idiopathic disorder featuring resting tremor, rigidity, bradykinesia, and postural instability. Pathologically, it is associated with degeneration of nigral dopaminergic neurons and formation of neuronal Lewy bodies, eosinophilic cytoplasmic inclusions containing α -synuclein. Although the true prevalence of all inherited forms of Parkinson's disease is unclear, rare cases of dominant PD have been associated with missense mutations in α -synuclein.⁷⁷ More recently, genomic triplication of the α -synuclein locus has been associated with dominant parkinsonism.⁷⁸ Feany and Bender³⁷ described a fly model of Parkinson's disease using misexpression of wild-type and mutant α -synuclein. Both wild-type and mutant forms of α -synuclein induced loss of tyrosine hydroxylase-immunoreactive neurons in the central brain of the fly, as assessed using immunohistochemistry of paraffin sections. Intracytoplasmic and neuritic accumulation of α -synuclein was observed, suggestive of Lewy bodies and Lewy neurites, respectively. Both wild-type and mutant α -synuclein resulted in progressive motor impairment. Very mild retinal degeneration was reported in aged flies expressing wild-type α -synuclein.

Bonini and colleagues⁷⁹ examined effects of chaperonin misexpression on α -synuclein phenotypes in *Drosophila*. They were unable to demonstrate abnormal motor behavior in flies expressing α -synuclein. These authors reported that overexpression of HSPA1L partially rescued dopaminergic degeneration induced by α -synuclein without affecting the appearance of α -synuclein-containing inclusions. A transgene encoding a dominant negative version of a constitutively expressed *Drosophila* hsp70 enhanced α -synuclein-induced degeneration. Of interest, this transgene when overexpressed in dopaminergic neurons itself had negative effects independent of α -synuclein, suggesting that endogenous chaperonin activity regulates survival of dopaminergic neurons. Bonini and Auluck and colleagues^{80,81} also showed that feeding flies with geldanamycin, which acts to upregulate chaperonins, also protected against α -synuclein-induced toxicity in dopaminergic neurons.

A number of additional papers have reported chemical and genetic modifiers of α -synuclein toxicity in *Drosophila*.^{82–84} However, the significance of the α -synuclein model has been called into question by recent work by Mardon and colleagues,⁸⁵ who used whole mount confocal analysis

of tyrosine hydroxylase staining in brain and were unable to demonstrate any neurodegeneration using a number of different α -synuclein lines. Nor were these authors able to demonstrate any abnormal behaviors or retinal degeneration induced by α -synuclein. It is possible that variations in food or environment are responsible for these variations in α -synuclein toxicity from lab to lab.

Parkin

The identification of mutations in parkin associated with autosomal recessive juvenile parkinsonism (AR-JP)⁸⁶ has provided new insights into the pathogenesis of both sporadic and familial forms of PD. Point mutations, deletions, and compound heterozygosity for mutations have been identified.⁸⁷ Studies of genetically derived animal models have attempted to define the relationship between parkin mutations and survival of dopaminergic neurons. However, with the exception of cell loss in locus coeruleus in one knockout,⁸⁸ loss of function studies of parkin in mouse have failed to produce robust cell loss.^{89–91} A homolog of parkin exists in *Drosophila*. Pallanck and colleagues² reported that parkin mutations in the fly cause cell death of sperm and indirect flight muscles. Marden and co-workers³ independently generated loss of function mutations and also found that these lead to reductions in cell size and increased susceptibility to oxidative stress. However, neither of these groups of investigators demonstrated that parkin mutations affect survival of DA neurons.

SUMMARY AND PERSPECTIVES

Transgenic models in the fly using targeted misexpression of human neurodegenerative disease-associated proteins have been established. These include models for HD and other glutamine repeat disorders, noncoding trinucleotide repeat expansions, models of amyloid pathology and tauopathies of relevance to AD, and models studying α -synuclein and parkin that pertain to PD. In many instances, robust neurodegeneration is observed in fly models, a distinct advantage as compared with mouse models. In some instances, fly models develop pathological lesions seen in disease, such as inclusion bodies and NFT seen in HD and AD, respectively. However, it is unreasonable to expect fly models to fully recapitulate all features of human disease. Rather, fly models should be viewed as sensitized genetic systems that permit the awesome power of fly genetics to be harnessed in an effort to isolate modifier genes or screen compound libraries at a speed that might be difficult if not impossible to accomplish in mice. Without question, such screens may identify modifiers that are irrelevant to neurodegenerative pathways, but fly models are a good place to start and have begun to provide valuable insight into disease and identify useful compounds. Hopefully, as techniques for

analysis improve and become more standardized, fly models will play important roles in our quest to develop cures for neurodegenerative disorders.

Acknowledgments: Thanks to Mel Feany for the ataxin-1 flies, Nancy Bonini for the ataxin-3 and HSPA1 flies, Parsa Kazemi-Esfarjani for the HDJ1 flies, Leslie Thompson and Larry Marsh for the Q108 and htt exon 1 flies, and Huda Zoghbi for the ataxin-1 antibody. This work was supported by grants from the National Institutes of Health (NS002116, NS046489, AG016570, and ES012078) and the American Parkinson's Disease Association (to G.R.J.) and a John J. Wasmuth Post-doctoral Fellowship of the Hereditary Disease Foundation (to T.-K.S.).

REFERENCES

1. Satterfield TF, Jackson SM, Pallanck LJ. A *Drosophila* homolog of the polyglutamine disease gene SCA2 is a dosage-sensitive regulator of actin filament formation. *Genet* 162:1687–1702, 2002.
2. Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ. Mitochondrial pathology and apoptotic muscle degeneration in *Drosophila* parkin mutants. *Proc Natl Acad Sci USA* 100:4078–4083, 2003.
3. Pesah Y, Pham T, Burgess H, Middlebrooks B, Verstreken P, Zhou Y et al. *Drosophila* parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. *Development* 131:2183–2194, 2004.
4. Zhang S, Xu L, Lee J, Xu T. *Drosophila* atrophin homolog functions as a transcriptional corepressor in multiple developmental processes. *Cell* 108:45–56, 2002.
5. Gunawardena S, Her LS, Brusch RG, Laymon RA, Niesman IR, Gordeky-Gold B, et al. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in *Drosophila*. *Neuron* 40:25–40, 2003.
6. Sharma RP, Chopra VL. Effect of the Wingless (wg1) mutation on wing and haltere development in *Drosophila melanogaster*. *Dev Biol* 48:461–465, 1976.
7. Bejsovec A. Wnt pathway activation: new relations and locations. *Cell* 120:11–14, 2005.
8. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. *Cell* 72:971–983, 1993.
9. Zoghbi HY, Orr HT. Glutamine repeats and neurodegeneration. *Annu Rev Neurosci* 23:217–247, 2000.
10. Warrick JM, Paulson HL, Gray-Board GL, Bui QT, Fischbeck KH, Pittman RN, et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in *Drosophila*. *Cell* 93:939–949, 1998.
11. Jackson GR, Salecker I, Dong X, Yao X, Arnheim N, Faber PW, et al. Polyglutamine-expanded human huntingtin transgenes induce degeneration of *Drosophila* photoreceptor neurons. *Neuron* 21:633–642, 1998.
12. Cummings CJ, Mancini MA, Antalffy B, DeFranco DB, Orr HT, Zoghbi HY. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. *Nat Genet* 19:148–154, 1998.
13. Chai Y, Koppenhafer SL, Bonini NM, Paulson HL. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. *J Neurosci* 19:10338–10347, 1999.
14. Chai Y, Koppenhafer SL, Shoemith SJ, Perez MK, Paulson HL. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. *Hum Mol Genet* 8:673–682, 1999.
15. Suhr ST, Senut MC, Whitelegge JP, Faull KF, Cuizon DB, Gage FH. Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression. *J Cell Biol* 153:283–294, 2001.
16. Qin ZH, Wang Y, Sapp E, Cuiffo B, Wanker E, Hayden MR, et al. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. *J Neurosci* 24:269–281, 2004.

17. Warrick JM, Chan HY, Gray-Board GL, Chai Y, Paulson HL, Bonini NM. Suppression of polyglutamine-mediated neurodegeneration in *Drosophila* by the molecular chaperone HSP70. *Nat Genet* 23:425–428, 1999.
18. Kazemi-Esfarjani P, Benzer S. Genetic suppression of polyglutamine toxicity in *Drosophila*. *Science* 287:1837–1840, 2000.
19. Ghosh S, Feany MB. Comparison of pathways controlling toxicity in the eye and brain in *Drosophila* models of human neurodegenerative diseases. *Hum Mol Genet* 13:2011–2018, 2004.
20. Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM, et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. *Nature* 399:263–267, 1999.
21. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. *Nat Med* 6:797–801, 2000.
22. Hersch S, Fink K, Vonsattel JP, Friedlander RM. Minocycline is protective in a mouse model of Huntington's disease. *Ann Neurol* 54:841, 2003.
23. Thomas M, Ashizawa T, Jankovic J. Minocycline in Huntington's disease: a pilot study. *Mov Disord* 19:692–695, 2004.
24. Hay BA, Wolff T, Rubin GM. Expression of baculovirus P35 prevents cell death in *Drosophila*. *Development* 120:2121–2129, 1994.
25. Hay BA, Wassarman DA, Rubin GM. *Drosophila* homologs of baculovirus inhibitor of apoptosis proteins function to block cell death. *Cell* 83:1253–1262, 1995.
26. Sang TK, Li C, Liu W, Rodriguez A, Abrams JM, Zipursky SL, et al. Inactivation of *Drosophila* Apaf-1 related killer suppresses formation of polyglutamine aggregates and blocks polyglutamine pathogenesis. *Hum Mol Genet* 14:357–372, 2005.
27. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. *Nature* 431:805–810, 2004.
28. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in *Drosophila*. *Nature* 413:739–743, 2001.
29. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. *J Neurosci* 23:9418–9427, 2003.
30. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. *Proc Natl Acad Sci USA* 100:2041–2046, 2003.
31. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. *Nat Genet* 36:585–595, 2004.
32. Pollitt SK, Pallos J, Shao J, Desai UA, Ma AA, Thompson LM, et al. A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. *Neuron* 40:685–694, 2003.
33. Kazantsev A, Walker HA, Slepko N, Bear JE, Preisinger E, Steffan JS, et al. A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in *Drosophila*. *Nat Genet* 30:367–376, 2002.
34. Marsh JL, Walker H, Theisen H, Zhu YZ, Fielder T, Purcell J, et al. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in *Drosophila*. *Hum Mol Genet* 9:13–25, 2000.
35. Kazemi-Esfarjani P, Benzer S. Suppression of polyglutamine toxicity by a *Drosophila* homolog of myeloid leukemia factor 1. *Hum Mol Genet* 11:2657–2672, 2002.
36. Higashiyama H, Hirose F, Yamaguchi M, Inoue YH, Fujikake N, Matsukage A, et al. Identification of ter94, *Drosophila* VCP, as a modulator of polyglutamine-induced neurodegeneration. *Cell Death Differ* 9:264–273, 2002.
37. Feany MB, Bender WW. A *Drosophila* model of Parkinson's disease. *Nature* 404:394–398, 2000.
38. Fernandez-Funez P, Nino-Rosales ML, de Gouyon B, She WC, Luchak JM, Martinez P, et al. Identification of genes that modify ataxin-1-induced neurodegeneration. *Nature* 408:101–106, 2000.
39. Tsai CC, Kao HY, Mitzutani A, Banayo E, Rajan H, McKeown M, et al. Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors. *Proc Natl Acad Sci USA* 101:4047–4052, 2004.
40. Warrick JM, Morabito LM, Bilen J, Gordesky-Gold B, Faust LZ, Paulson HL, et al. Ataxin-3 suppresses polyglutamine neurodegeneration in *Drosophila* by a ubiquitin-associated mechanism. *Mol Cell* 18:37–48, 2005.
41. Steffan JS, Agrawal N, Pallos J, Rockabrand E, Trotman LC, Slepko N, et al. SUMO modification of Huntingtin and Huntingtin's disease pathology. *Science* 304:100–104, 2004.
42. Lee WC, Yoshihara M, Littleton JT. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a *Drosophila* model of Huntington's disease. *Proc Natl Acad Sci USA* 101:3224–3229, 2004.
43. Takeyama K, Ito S, Yamamoto A, Tanimoto H, Furutani T, Kanuka H, et al. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in *Drosophila*. *Neuron* 35:855–864.
44. Chan HY, Warrick JM, Andriola I, Merry D, Bonini NM. Genetic modulation of polyglutamine toxicity by protein conjugation pathways in *Drosophila*. *Hum Mol Genet* 11:2895–2904, 2002.
45. Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, Cavalcanti F, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. *Science* 271:1423–1427, 1996.
46. Koob MD, Moseley ML, Schut LJ, Benzow KA, Bird TD, Day JW, et al. An untranslated CTG expansion causes a novel form of spinocerebellar ataxia (SCA8). *Nat Genet* 21:379–384, 1999.
47. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. *Cell* 68:799–808, 1992.
48. Mutsuddi M, Marshall CM, Benzow KA, Koob MD, Rebay I. The spinocerebellar ataxia 8 noncoding RNA causes neurodegeneration and associates with staufen in *Drosophila*. *Curr Biol* 14:302–308, 2004.
49. Houseley JM, Wang Z, Brock GJ, Soloway J, Artero R, Perez-Alonso M, et al. Myotonic dystrophy associated expanded CUG repeat muscleblind positive ribonuclear foci are not toxic to *Drosophila*. *Hum Mol Genet* 14:873–883, 2005.
50. Kremer EJ, Pritchard M, Lynch M, Yu S, Holman K, Baker E, et al. Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n. *Science* 252:1711–1714, 1991.
51. Jin P, Zarnescu DC, Zhang F, Pearson CE, Lucchesi JC, Moses K, et al. RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in *Drosophila*. *Neuron* 39:739–747, 2003.
52. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. *Cell* 120:545–555, 2005.
53. Alzheimer's Disease Collaborative Group. The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. *Nat Genet* 11:219–222, 1995.
54. Tanzi RE, Vaula G, Romano DM, Mortilla M, Huang TL, Tupler RG, et al. Assessment of amyloid β -protein precursor gene mutations in a large set of familial and sporadic Alzheimer disease cases. *Am J Hum Genet* 51:273–282, 1992.
55. Luo L, Tully T, White K. Human amyloid precursor protein ameliorates behavioral deficit of flies deleted for Appl gene. *Neuron* 9:595–605, 1992.
56. Torroja L, Chu H, Kotovsky I, White K. Neuronal overexpression of APPL, the *Drosophila* homologue of the amyloid precursor protein (APP), disrupts axonal transport. *Curr Biol* 9:489–492, 1999.
57. Iijima K, Liu HP, Chiang AS, Hearn SA, Konsolaki M, Zhong Y. Dissecting the pathological effects of human A β 40 and A β 42 in *Drosophila*: a potential model for Alzheimer's disease. *Proc Natl Acad Sci USA* 101:6623–6628, 2004.
58. Finelli A, Kelkar A, Song HJ, Yang H, Konsolaki M. A model for studying Alzheimer's A β 42-induced toxicity in *Drosophila* melanogaster. *Mol Cell Neurosci* 26:365–375, 2004.

59. Iwata N, Tsubuki S, Takaki Y, et al. Metabolic regulation of brain A β by neprilysin. *Science* 292:1550–1552, 2001.
60. Greeve I, Kretzschmar D, Tschape JA, Beyn A, Brellinger C, Schweizer M, et al. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic *Drosophila*. *J Neurosci* 24:3899–3906, 2004.
61. Gunawardena S, Goldstein LS. Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in *Drosophila*. *Neuron* 32:389–401, 2001.
62. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. *Science* 307:1282–1288, 2005.
63. Struhl G, Greenwald I. Presenilin is required for activity and nuclear access of Notch in *Drosophila*. *Nature* 398:522–525, 1999.
64. Ye Y, Lukinova N, Fortini ME. Neurogenic phenotypes and altered Notch processing in *Drosophila* Presenilin mutants. *Nature* 398:525–529, 1999.
65. Francis R, McGrath G, Zhang J, Ruddy DA, Sym M, Apfeld J, et al. Aph-1 and pen-2 are required for Notch pathway signaling, γ -secretase cleavage of β APP, and presenilin protein accumulation. *Dev Cell* 3:85–97, 2002.
66. Niimura M, Isoo N, Takasugi N, Tsuruoka M, Ui-Tei K, Saigo K, et al. Aph-1 contributes to the stabilization and trafficking of the γ -secretase complex through mechanisms involving intermolecular and intramolecular interactions. *J Biol Chem* 280:12967–12975, 2005.
67. Guo M, Hong EJ, Fernandes J, Zipursky SL, Hay BA. A reporter for amyloid precursor protein γ -secretase activity in *Drosophila*. *Hum Mol Genet* 12:2669–2678, 2003.
68. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. *Annu Rev Neurosci* 24:1121–1159, 2001.
69. Heidary G, Fortini ME. Identification and characterization of the *Drosophila* tau homolog. *Mech Dev* 108:171–178, 2001.
70. Williams DW, Tyrer M, Shepherd D. Tau and tau reporters disrupt central projections of sensory neurons in *Drosophila*. *J Comp Neurol* 428:630–640, 2000.
71. Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, Squire A, et al. GSK-3 β inhibition reverses axonal transport defects and behavioural phenotypes in *Drosophila*. *Mol Psychiatry* 9:522–530, 2004.
72. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, et al. Tauopathy in *Drosophila*: neurodegeneration without neurofibrillary tangles. *Science* 293:711–714, 2001.
73. Shulman JM, Feany MB. Genetic modifiers of tauopathy in *Drosophila*. *Genet* 165:1233–1242, 2003.
74. Mershin A, Pavlopoulos E, Fitch O, Braden BC, Nanopoulos DV, Skoulakis EM. Learning and memory deficits upon TAU accumulation in *Drosophila* mushroom body neurons. *Learn Mem* 11:277–287, 2004.
75. Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA, Massachi S, et al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in *Drosophila*. *Neuron* 34:509–519, 2002.
76. Nishimura I, Yang Y, Lu B. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in *Drosophila*. *Cell* 116:671–682, 2004.
77. Vila M, Przedborski S. Genetic clues to the pathogenesis of Parkinson's disease. *Nat Med* 10:S58–S62, 2004.
78. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. α -Synuclein locus triplication causes Parkinson's disease. *Science* 302:841, 2003.
79. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of α -synuclein toxicity in a *Drosophila* model for Parkinson's disease. *Science* 295:865–868, 2002.
80. Auluck PK, Bonini NM. Pharmacological prevention of Parkinson disease in *Drosophila*. *Nat Med* 8:1185–1186, 2002.
81. Auluck PK, Meulener MC, Bonini NM. Mechanisms of suppression of α -synuclein neurotoxicity by geldanamycin in *Drosophila*. *J Biol Chem* 280:2873–2878, 2005.
82. Pendleton RG, Parvez F, Sayed M, Hillman R. Effects of pharmacological agents upon a transgenic model of Parkinson's disease in *Drosophila melanogaster*. *J Pharmacol Exp Ther* 300:91–96, 2002.
83. Yang Y, Nishimura I, Imai Y, Takahashi R, Lu B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in *Drosophila*. *Neuron* 37:911–924, 2003.
84. Haywood AF, Staveley BE. Parkin counteracts symptoms in a *Drosophila* model of Parkinson's disease. *BMC Neurosci* 5:14, 2004.
85. Pesah Y, Burgess H, Middlebrooks B, et al. Whole-mount analysis reveals normal numbers of dopaminergic neurons following misexpression of α -synuclein in *Drosophila*. *Genesis* 41:154–159, 2005.
86. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. *Nature* 392:605–608, 1998.
87. Hattori N, Mizuno Y. Pathogenetic mechanisms of parkin in Parkinson's disease. *Lancet* 364:722–724, 2004.
88. Von Coelln R, Thomas B, Savitt JM, Lim KL, Sasaki M, Hess EJ, et al. Loss of locus coeruleus neurons and reduced startle in parkin null mice. *Proc Natl Acad Sci USA* 101:10744–10749, 2004.
89. Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. *J Biol Chem* 278:43628–43635, 2003.
90. Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. *Hum Mol Genet* 12:2277–2291, 2003.
91. Perez FA, Palmiter RD. Parkin-deficient mice are not a robust model of parkinsonism. *Proc Natl Acad Sci USA* 102:2174–2179, 2005.